



# **DENIS CHEM LAB LIMITED**

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

30<sup>th</sup> May, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001

**Company Code No. 537536**

Dear Sir,

**Sub: - Outcome of Board Meeting**

**- Submission of Audited Financial Results for the financial year ended on 31<sup>st</sup> March, 2025**

We refer to our letter dated 19<sup>th</sup> May, 2025 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors of the Company, in their meeting held today i.e. on 30<sup>th</sup> May, 2025, *interalia*, has:

1. Approved the Standalone Audited Financial Statements of the Company for Quarter and Financial Year ended on 31<sup>st</sup> March, 2025 as recommended by the Audit Committee.
2. Recommended a Final dividend of Rs. 1.50 per Equity Share of Rs.10/- each for the financial year 2024-25 ended on 31<sup>st</sup> March, 2025, subject to approval of shareholders at the ensuing Annual General Meeting.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we enclose the following:

1. Statement of Audited Financial Results for the financial year ended on 31<sup>st</sup> March, 2025- Integrated Filing (Financial).
2. Auditors' Report on the Audited Financial Results for the financial year ended on 31<sup>st</sup> March, 2025.
3. Declaration to the effect that there is Unmodified Opinion with respect to Audited Financial Results for the financial year ended on 31<sup>st</sup> March, 2025.

The Meeting of Board of Directors was commenced at 10:00 a.m. and concluded at 1:45 p.m.

Thanking you,

Yours faithfully,  
for **DENIS CHEM LAB LIMITED**

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**(DIN: 00087114)**

Encl: As above

**SHAH & SHAH ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

702, ANIKET,  
Nr. MUNICIPAL MARKET,  
C.G. ROAD, NAVRANGPURA,  
AHMEDABAD - 380 009.  
PHONE: 26465433  
FAX : 079 - 26406983  
Email: ca@shahandshah.co.in

**INDEPENDENT AUDITOR'S REPORT ON FINANCIAL RESULTS OF DENIS CHEM LAB LIMITED PURSUANT TO REGULATIONS 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENT) REGULATIONS, 2015, AS AMENDED.**

**TO THE BOARD OF DIRECTORS OF DENIS CHEM LAB LIMITED**

**Report on the audit of the Financial Results**

**Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of **DENIS CHEM LAB LIMITED** ("the Company") for the quarter and year ended on 31st March 2025 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the quarter and year ended 31st March 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Financial Results**

These financial results have been prepared on the basis of the Financial Statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the applicable Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control, that we identify during our audit.



**SHAH & SHAH ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

702, ANIKET,  
Nr. MUNICIPAL MARKET,  
C.G. ROAD, NAVRANGPURA,  
AHMEDABAD - 380 009.  
PHONE: 26465433  
FAX : 079 - 26406983  
Email: ca@shahandshah.co.in

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter:**

The Statement includes the results for the quarter ended 31<sup>st</sup> March, 2025 and 31<sup>st</sup> March, 2024 being the balancing figure between audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2025 and 31<sup>st</sup> March, 2024 respectively and the published year to date figures up to the third quarter of the respective financial years which were subjected to limited review by us, as required under the Listing Regulations.

Our opinion is not qualified in respect of these matters.



Place : Ahmedabad  
Date : May 30, 2025

For **SHAH & SHAH ASSOCIATES**  
**Chartered Accountants**  
**Firm Regn. No. 113742W**

*V. C. Tanna*

**VASANT C. TANNA**  
**Partner**

**Membership No. 100422**  
**UDIN 25100422BMIIVG4974**



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

## A. FINANCIAL RESULTS:

### STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED ON 31<sup>ST</sup> MARCH, 2025

(Rs. In lakh)

Particulars		Quarter ended on			Year ended on	
		31-03-2025 (Audited) (Refer notes)	31-12-2024 (Unaudited)	31-03-2024 (Audited) (Refer notes)	31-03-2025 (Audited)	31-03-2024 (Audited)
	(Refer Notes Below)					
1	Revenue from operations	4,138.34	4,284.13	3,985.49	17,329.97	16,782.20
2	Other income	117.22	30.00	59.46	237.45	138.77
<b>3</b>	<b>Total Income (1+2)</b>	<b>4,255.56</b>	<b>4,314.13</b>	<b>4,044.95</b>	<b>17,567.42</b>	<b>16,920.97</b>
4	Expenses					
	a. Cost of Materials consumed	1,968.60	2,159.14	1,919.21	8,643.69	8,004.63
	b. Purchases of stock-in-trade	225.46	218.29	180.57	865.35	787.04
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	66.94	(23.72)	(53.80)	67.64	(101.48)
	d. Employee benefits expense	385.47	402.67	396.44	1,526.34	1,439.09
	e. Finance costs	23.05	6.73	23.46	51.04	54.32
	f. Depreciation & amortisation expense	173.16	183.66	174.93	686.10	694.55
	g. Other expenses	1,286.27	1,145.49	1,035.18	4,616.12	4,529.60
	<b>Total Expenses</b>	<b>4,128.95</b>	<b>4,092.27</b>	<b>3,675.99</b>	<b>16,456.28</b>	<b>15,407.75</b>
5	Profit/ (Loss) before exceptional items and tax (3-4)	<b>126.61</b>	<b>221.86</b>	<b>368.96</b>	<b>1,111.14</b>	<b>1,513.22</b>
6	Exceptional items					-
7	Profit / (Loss) before tax (5-6)	<b>126.61</b>	<b>221.86</b>	<b>368.96</b>	<b>1,111.14</b>	<b>1,513.22</b>
8	Tax expense:					
	Current tax	100.87	2.51	121.80	322.50	462.00
	Deferred tax	(45.01)	43.21	(25.76)	(89.76)	(88.98)
	Short/(Excess) provision of earlier years	-	-	-	70.82	24.62
<b>9</b>	<b>Profit/ (Loss) for the period from continuing operations (7-8)</b>	<b>70.75</b>	<b>176.14</b>	<b>272.92</b>	<b>807.58</b>	<b>1,115.58</b>
10	Profit/ (loss) from discontinuing operations before Tax	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/ (loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
<b>13</b>	<b>Profit/ (Loss) for the period (9+12)</b>	<b>70.75</b>	<b>176.14</b>	<b>272.92</b>	<b>807.58</b>	<b>1,115.58</b>



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

Particulars		Quarter ended on			Year ended on	
		31-03-2025 (Audited) (Refer notes)	31-12-2024 (Unaudited)	31-03-2024 (Audited) (Refer notes)	31-03-2025 (Audited)	31-03-2024 (Audited)
14	Other Comprehensive Income					
	<i>Items that will not be reclassified subsequently to profit or loss</i>					
	Gain/(loss) on re-measurement of defined benefit plan	17.52	-	(37.03)	17.52	(37.03)
	Income tax relating to items that will not be reclassified to profit or loss	(4.41)	-	9.32	(4.41)	9.32
	<i>Items that will be reclassified subsequently to profit or loss</i>	-	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Other Comprehensive Income, net of tax</b>	<b>13.11</b>	<b>-</b>	<b>(27.71)</b>	<b>13.11</b>	<b>(27.71)</b>
15	Total Comprehensive Income for the period (13+14)	83.86	<b>176.14</b>	<b>245.21</b>	<b>820.69</b>	<b>1,087.87</b>
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	1,387.67	1,387.67	1,387.67	1,387.67	1,387.67
17	Reserves excluding Revaluation Reserves				7,122.75	6,648.98
18	Earnings Per Share of Rs. 10/- each (for continuing operations)					
	Basic	0.51	1.27	1.97	5.82	8.04
	Diluted	0.51	1.27	1.97	5.82	8.04
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)					
	Basic	-	-	-	-	-
	- Diluted	-	-	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)					
	- Basic	0.51	1.27	1.97	5.82	8.04
	- Diluted	0.51	1.27	1.97	5.82	8.04



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

## NOTES:

Sr.	Particulars
1.	These financial results were reviewed by the audit committee and thereafter have been approved by the Board of Directors at their respective meetings held on May 30, 2025. The Statutory Auditors have conducted audit of these financial results and issued an unmodified opinion on the same.
2.	These audited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as “IND AS”) prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules as amended from time to time. (Indian Accounting Standard) Rules as amended from time to time.
3.	Figures for the quarter ended on 31 <sup>st</sup> March, 2025 and 31 <sup>st</sup> March, 2024, represents the balancing figures between the audited figures for the full Financial Year ended on 31 <sup>st</sup> March, 2025 and 31 <sup>st</sup> March, 2024 and Unaudited year to date figures for the nine months upto 31 <sup>st</sup> December, 2024 and 31 <sup>st</sup> December, 2023 respectively.
4.	The Company is operating only in one segment i.e. manufacturing & sales of transfusion solutions in bottles.
5.	The Company does not have any subsidiary / associate.
6.	The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020 and has invited suggestions from the stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the said code become effective including related rules framed thereunder to determine the financial impact are published.
7.	During the quarter ended on 31 <sup>st</sup> December, 2024, the Company received an order together with demand (including penalty) of Rs.12.09 crores from the office of the Commissioner Central GST & Central Excise, Ahmedabad - Gandhinagar for the period commencing from May 2000 to June 2017 in relation to classification of multiple products in the form of “intravenous fluids” manufactured by the Company and cleared under the benefit of exemption/concessional rate of duty. The Company has preferred an appeal before the Customs, Excise and Service Tax Appellate Tribunal (CESTAT) and based on the facts and merits of the case the management of the Company is confident about favorable outcome of the same.
8.	The Balance Sheet and Cash Flow Statement are attached as per Annexure-I and Annexure-II respectively.
9.	The figures for the corresponding previous year/period's have been regrouped/rearranged wherever necessary.
10.	The Board of Directors of the Company has recommended final dividend of Rs. 1.50 (@15%) per Equity Share of Rs.10/- each for the financial year ended on 31 <sup>st</sup> March, 2025, subject to approval of shareholders at the ensuing Annual General Meeting.

**For DENIS CHEM LAB LIMITED**

Date : 30<sup>th</sup> May, 2025  
Place : Ahmedabad

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**DIN: 00087114**



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

## Annexure-I

### STATEMENT OF ASSETS AND LIABILITIES:

(Rs. In lakh)

Sr. No.	Particulars	As at 31-03-2025	As at 31-03-2024
	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	Property, plant and equipment	3,871.80	3,744.18
	Capital work-in-progress	7.18	22.36
	Investment property	-	-
	Goodwill	-	-
	Other intangible Assets	10.70	17.81
	Intangible Assets under development	-	-
	Investments accounted for using equity method	-	-
	Biological Assets other than bearer plants	-	-
	Non-Current Financial Assets:	-	-
	(i) Investments, Non-Current	-	-
	(ii) Trade receivables, Non-Current	-	-
	(iii) Loans, Non-Current	-	-
	(iv) Other non current financial asset	216.14	127.02
	Income Tax Asset	17.51	18.28
	Deferred tax Assets (net)	-	-
	Other Non-Current Assets	39.44	68.02
	<b>Total Non-Current Assets</b>	<b>4,162.76</b>	<b>3,997.67</b>
2	<b>Current Assets</b>		
	Inventories	980.88	1,018.97
	Current financial asset:		
	(i) Current investments	-	-
	(ii) Trade receivables, Current	3,061.48	3,165.89
	(iii) Cash and cash equivalents	85.03	119.33
	(iv) Bank balance other than above	2,538.34	2,395.64
	(v) Loans, Current	-	-
	(vi) Other Current financial Assets	164.33	64.58
	Current tax Assets (net)	-	-
	Other Current Assets	234.41	172.79
	<b>Total Current Assets</b>	<b>7,064.47</b>	<b>6,937.20</b>
	<b>TOTAL ASSETS</b>	<b>11,227.24</b>	<b>10,934.87</b>



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

(Rs. In lakh)

Sr. No.	Particulars	As at 31-03-2025	As at 31-03-2024
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	Equity share capital	1,387.67	1,387.67
	Other Equity	7,122.75	6,648.98
	<b>Total Equity</b>	<b>8,510.42</b>	<b>8,036.65</b>
<b>2</b>	<b>Liabilities</b>		
	<b>Non-Current Liabilities</b>		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	45.31	45.17
	(ii) Trade payables, Non-Current	-	-
	(a) total outstanding dues of micro enterprises and small enterprises	-	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-
	(iii) Other Non-Current financial Liabilities	43.45	37.34
	Provisions, Non-Current	10.81	96.16
	Deferred tax Liabilities (net)	-	-
	Deferred government grants, non current	-	-
	Other Non-Current Liabilities	-	-
	<b>Total Non-Current Liabilities</b>	<b>99.57</b>	<b>178.67</b>
	<b>Current Liabilities</b>		
	Current financial Liabilities:		
	(i) Borrowings, Current	36.73	59.43
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises	340.91	-
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	1,782.85	2,140.83
	(iii) Other Current financial Liabilities	334.51	292.87
	Other Current Liabilities	77.06	40.24
	Provisions, Current	5.78	50.61
	Current tax Liabilities (Net)	39.41	135.57
	Deferred government grants, current	-	-
	<b>Total Current Liabilities</b>	<b>2,617.25</b>	<b>2,719.55</b>
	<b>Total Liabilities</b>	<b>2,716.82</b>	<b>2,898.22</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>11,227.24</b>	<b>10,934.87</b>



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

## Annexure-II

### STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2025

(Rs. In lakh)

Particulars	For the year ended 31 <sup>st</sup> March, 2025	For the year ended 31st March, 2024
<b>(A) Cash flow from operating activities</b>		
Profit before tax	1,111.14	1,513.22
<b>Adjustment for:</b>		
Finance Costs	51.04	54.32
Depreciation and amortisation	686.10	694.55
Interest received	(183.83)	(127.50)
profit On sale of Assets (Net)	-	-
Reversal of Provision for Expected Credit Loss (ECL)	17.52	(37.03)
Unrealised foreign exchange fluctuation (gain)/loss	-	-
Remeasurement of defined benefit obligations	-	-
<b>Operating Profit / (Loss) before working capital changes</b>	<b>1,681.97</b>	<b>2,097.57</b>
<b>Changes in working capital:</b>		
(Increase)/Decrease in Inventories	38.09	(106.59)
(Increase)/Decrease in Trade Receivables	104.41	(41.83)
(Increase)/Decrease in Other Financial Assets	(87.64)	24.83
(Increase)/Decrease in Other Assets	(61.62)	(69.11)
Increase/(Decrease) in Trade Payables	(17.07)	312.69
Increase/(Decrease) in Provisions	(38.73)	60.43
Increase / (Decrease) in Other Current Liabilities	36.83	(27.13)
Increase / (Decrease) in Other Liabilities	41.64	(35.20)
<b>Cash generated / (used in) from operations</b>	<b>1,697.88</b>	<b>2,215.65</b>
Less : Tax Paid (net of refunds, if any)	(488.69)	(434.19)
<b>Net Cash generated from operating activities (A)</b>	<b>1,209.19</b>	<b>1,781.47</b>
<b>(B) Cash flow from investing activities</b>		
Capital expenditure on Property, Plant and Equipment, Intangible assets, Capital Work in progress	(762.84)	(692.78)
Insurance claim received for fixed assets	-	-
Interest received	82.58	106.38
Bank deposits / margin money withdrawn / (placed) (net)	(142.71)	(903.05)
<b>Net Cash used in investing activities (B)</b>	<b>(822.97)</b>	<b>(1,489.45)</b>



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

(Rs. In lakh)

Particulars	For the year ended 31st March, 2025	For the year ended 31st March, 2024
<b>(C) Cash flow from financing activities</b>		
Dividend and dividend tax paid	(346.92)	(277.53)
Increase/(Decrease) in Short-term borrowings	(22.70)	(41.86)
Increase/(Decrease) in Long-term borrowings	0.14	(46.90)
Finance Costs Paid	(51.04)	(54.32)
Unrealised foreign exchange fluctuation (gain)/loss		-
<b>Net Cash generated from financing activities (C)</b>	<b>(420.52)</b>	<b>(420.62)</b>
<b>Net Increase / (Decrease) in cash and cash equivalents (A)+(B)+(C)</b>	<b>(34.30)</b>	<b>(128.60)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>119.33</b>	<b>247.93</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>85.03</b>	<b>119.33</b>
<b>Notes to Cash flow Statement :</b>		
<b>Cash and cash equivalents as per above comprise of the following :</b>		
Cash and cash equivalents	85.03	119.33
<b>Balances as per statement of cash flows</b>	<b>85.03</b>	<b>119.33</b>

For DENIS CHEM LAB LIMITED

Date : 30<sup>th</sup> May, 2025  
Place : Ahmedabad

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**DIN: 00087114**



# DENIS CHEM LAB LIMITED

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

**: Not Applicable**

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

**: Not Applicable**

Sr. No.	Particulars	in INR crore
<b>1.</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short-term and long-term debt</b>	0

**D. DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR HALF YEAR ENDED 31ST MARCH, 2025:**

**As per Annexure - III**

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

**: Not Applicable**

**For DENIS CHEM LAB LIMITED**

Date : 30<sup>th</sup> May, 2025  
Place : Ahmedabad

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**DIN: 00087114**



# **DENIS CHEM LAB LIMITED**

MANUFACTURERS OF PARENTERAL PRODUCTS

[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA  
TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: [denischem401@gmail.com](mailto:denischem401@gmail.com)

30<sup>th</sup> May, 2025

**BSE Limited**

PhirozeJeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**Company Code No. 537536**

Dear Sir,

**Sub: Declaration regarding Audit report with unmodified opinion with respect to Annual Audited Financial Results for the Financial Year ended 31<sup>st</sup> March, 2025**

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016, it is hereby declared and confirmed that Auditors' Report obtained from the Statutory Auditors, M/s. Shah & Shah Associates, Chartered Accountants on Annual Audited Financial Results of the Company for the financial year ended 31<sup>st</sup> March, 2025 has an unmodified opinion.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

for **DENIS CHEM LAB LIMITED**

**HIMANSHU C. PATEL**  
**MANAGING DIRECTOR**  
**(DIN: 00087114)**

